SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.6 Revision Date: 27.08.2021 SDS Number: 415344-00017 Date of last issue: 09.04.2021 Date of first issue: 14.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Mometasone / Clotrimazole / Gentamicin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
Company : MSD Kilsheelan Clonmel Tipperary, IE
Telephone : 353-51-601000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Reproductive toxicity, Category 1A H360D: May damage the unborn child.
Short-term (acute) aquatic hazard, Category 1 H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms :

Signal word : Danger

Hazard statements :
H360D May damage the unborn child.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:
Gentamicin

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>clotrimazole</td>
<td>23593-75-1 245-764-8</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repir. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410

M-Factor (Acute aquatic toxicity): 10
# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006

## Mometasone / Clotrimazole / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

### M-Factor (Chronic aquatic toxicity): 10

- Acute toxicity estimate
- Acute dermal toxicity: 923 mg/kg

### Gentamicin

- **Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear)**
- **Aquatic Acute 1; H400**
- **Aquatic Chronic 1; H410**

### M-Factor (Acute aquatic toxicity): 100

M-Factor (Chronic aquatic toxicity): 1

### Mometasone

- **Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin)**
- **Aquatic Chronic 1; H410**

### M-Factor (Chronic aquatic toxicity): 100

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

**General advice:**
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders:**
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled:**
If inhaled, remove to fresh air. Get medical attention.

**In case of skin contact:**
In case of contact, immediately flush skin with soap and plenty of water.
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyeing or other appropriate containment to keep material from spreading. If dyed material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil</td>
<td>8042-47-5</td>
<td>TWA (Vapour)</td>
<td>50 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>(petroleum)</td>
<td></td>
<td>TWA (Mist and particles)</td>
<td>1 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**
- Chemical-resistant gloves

**Remarks**
- Consider double gloving.

**Skin and body protection**
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to NS EN 14387

**Filter type**
- Combined particulates and organic vapour type (A-P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>suspension</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>oily</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Mometasone / Clotrimazole / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6</td>
<td>27.08.2021</td>
<td>415344-00017</td>
<td>09.04.2021</td>
</tr>
</tbody>
</table>

- Auto-ignition temperature: No data available
- Decomposition temperature: No data available
- pH: No data available
- Viscosity
  - Viscosity, kinematic: No data available
- Solubility(ies)
  - Water solubility: No data available
- Partition coefficient: n-octanol/water: Not applicable
- Vapour pressure: No data available
- Relative density: No data available
- Density: No data available
- Relative vapour density: No data available
- Particle characteristics
  - Particle size: Not applicable

9.2 Other information
- Explosives: Not explosive
- Oxidizing properties: The substance or mixture is not classified as oxidizing.
- Evaporation rate: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents
10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
- Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
  Method: Calculation method

- Acute dermal toxicity: Acute toxicity estimate: > 2.000 mg/kg
  Method: Calculation method

Components:

- clotrimazole:
  - Acute oral toxicity: LD50 (Rat): 708 mg/kg
    LD50 (Mouse): 761 mg/kg
    LD50 (Rabbit): > 1.000 mg/kg
  - Acute inhalation toxicity: LC50 (Rat): > 0,73 mg/l
    Exposure time: 4 h
    Test atmosphere: dust/mist
  - Acute dermal toxicity: LD50 (Mouse): 923 mg/kg
    Acute toxicity estimate: 923 mg/kg
    Method: Calculation method

- Gentamicin:
  - Acute oral toxicity: LD50 (Rat): 8.000 - 10.000 mg/kg
    LD50 (Mouse): 10.000 mg/kg
  - Acute inhalation toxicity: LC50 (Rat): > 0,2 mg/l
    Exposure time: 4 h
    Test atmosphere: dust/mist
    Remarks: No mortality observed at this dose.
  - Acute toxicity (other routes of administration): LD50 (Rat): 67 - 96 mg/kg
    Application Route: Intravenous
Mometasone / Clotrimazole / Gentamicin Formulation

LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

**Mometasone:**

- **Acute oral toxicity**: LD50 (Rat): > 2,000 mg/kg
  LD50 (Mouse): > 2,000 mg/kg

- **Acute inhalation toxicity**: LC50 (Rat): > 3.3 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Remarks: No mortality observed at this dose.

  LC50 (Mouse): > 3.2 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist

- **Acute toxicity (other routes of administration)**: LD50 (Rat): 300 mg/kg
  Application Route: Subcutaneous
  Symptoms: Breathing difficulties

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

- **clotrimazole**:
  Species: Rabbit
  Result: No skin irritation

- **Gentamicin**:
  Species: Rabbit
  Result: Mild skin irritation

- **Mometasone**:
  Species: Rabbit
  Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

- **clotrimazole**:
  Species: Rabbit
  Result: Mild eye irritation
Mometasone / Clotrimazole / Gentamicin Formulation

Gentamicin:
Species: Rabbit
Result: Mild eye irritation

Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Gentamicin:
Remarks: No data available

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

clotrimazole:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosome aberration test in vitro
Result: negative
Test Type: in vitro micronucleus test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Application Route: Oral
Result: negative

Test Type: Mammalian spermatogonial chromosome aberration test (in vivo)
Species: Hamster
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Gentamicin:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Mometasone:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity- Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

clotrimazole:
Species: Rat
Application Route: Oral
Exposure time: 78 weeks
Result: negative

Gentamicin:
Carcinogenicity - Assessment: No data available

Mometasone:
Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative
Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

clotrimazole:
Effects on fertility: Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: LOAEL: 50 mg/kg body weight
Result: Effects on fertility

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects
Test Type: Embryo-foetal development
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 180 mg/kg body weight  
Result: No effects on foetal development

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

Gentamicin:

Effects on fertility:  
Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Fertility: NOAEL: 20 mg/kg body weight  
Result: No significant adverse effects were reported

Effects on foetal development:  
Test Type: Embryo-foetal development  
Species: Rabbit  
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight  
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 75 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from
Mometasone / Clotrimazole / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

Assessment: human epidemiological studies.

Mometasone:
Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Subcutaneous
- Fertility: NOAEL: 0.015 mg/kg body weight
- Symptoms: Reduced embryonic survival, Reduced foetal weight
- Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Subcutaneous
  - Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
  - Result: Embryotoxic effects., Teratogenicity and developmental toxicity
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Dermal
  - Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-foetal toxicity
- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Dermal
  - Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Subcutaneous
  - Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  - Result: Effects on newborn
- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment:
- Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.
Mometasone / Clotrimazole / Gentamicin Formulation

Components:

Mometasone:
Remarks: Based on available data, the classification criteria are not met.

STOT - repeated exposure
Not classified based on available information.

Components:

clotrimazole:
Target Organs: Liver, Kidney, Adrenal gland
Assessment: May cause damage to organs through prolonged or repeated exposure.

Gentamicin:
Target Organs: Kidney, inner ear
Assessment: Causes damage to organs through prolonged or repeated exposure.

Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:

clotrimazole:
Species: Rabbit
LOAEL: 5 - 40 mg/kg
Application Route: Skin contact
Exposure time: 3 Weeks
Target Organs: Skin
Symptoms: Oedema, Fissuring, Necrosis, Redness

Species: Rat
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Liver, Kidney, Adrenal gland

Species: Dog
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 6 - 12 Months
Target Organs: Adrenal gland
Symptoms: Salivation, Lachrymation, Vomiting
Gentamicin:
Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks
Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks
Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 10 mg/kg
Application Route : Intramuscular
Exposure time : 52 Weeks
Target Organs : Kidney, Blood

Species : Rat
NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

Mometasone:
Species : Rat
NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
NOAEL : 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone:
Not applicable

11.2 Information on other hazards
Endocrine disrupting properties
Product: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure
Components:
clotrimazole:
Skin contact: Symptoms: Rash, Itching, Blistering, Oedema, Redness
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:
Ingestion: Target Organs: Kidney
Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching
Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

clotrimazole:
Toxicity to fish: LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.02 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l
Exposure time: 72 h
NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity): 10

Toxicity to microorganisms: EC50: > 10,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity): NOEC: 0.025 mg/l
Exposure time: 32 d
Species: Oncorhynchus mykiss (rainbow trout)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.01 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 10

Gentamicin:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
## Toxicity to algae/aquatic plants

<table>
<thead>
<tr>
<th>Method</th>
<th>EC50 (Pseudokirchneriella subcapitata (green algae))</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 201</td>
<td>10 µg/l</td>
<td>72 h</td>
<td></td>
</tr>
<tr>
<td>OECD Test Guideline 201</td>
<td>1,5 µg/l</td>
<td>72 h</td>
<td></td>
</tr>
<tr>
<td>OECD Test Guideline 201</td>
<td>4,7 µg/l</td>
<td>72 h</td>
<td></td>
</tr>
<tr>
<td>OECD Test Guideline 201</td>
<td>1,6 µg/l</td>
<td>72 h</td>
<td></td>
</tr>
</tbody>
</table>

## M-Factor (Acute aquatic toxicity)

<table>
<thead>
<tr>
<th>Method</th>
<th>EC50 : 288,7 mg/l</th>
<th>Exposure time</th>
<th>Test Type</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 209</td>
<td>3 h</td>
<td>Respiration inhibition</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Toxicity to microorganisms

<table>
<thead>
<tr>
<th>Method</th>
<th>EC50 : &gt; 5 mg/l</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 202</td>
<td>7 d</td>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

## Toxicity to fish

<table>
<thead>
<tr>
<th>Method</th>
<th>LC50 : 0,11 mg/l</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 202</td>
<td>96 h</td>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

## Toxicity to daphnia and other aquatic invertebrates

<table>
<thead>
<tr>
<th>Method</th>
<th>EC50 : &gt; 5 mg/l</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 202</td>
<td>48 h</td>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>

## Toxicity to algae/aquatic plants

<table>
<thead>
<tr>
<th>Method</th>
<th>EC50 : &gt; 3,2</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 202</td>
<td></td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>
Mometasone / Clotrimazole / Gentamicin Formulation

Toxicity to microorganisms

Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity)

Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

NOEC: 0.00014 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

Exposure time: 28 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

12.2 Persistence and degradability

Components:

clotrimazole:
Stability in water : Hydrolysis: 50 % (242 d)

Gentamicin:
Biodegradability : Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Mometasone:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 % (12 d)
Method: OECD Test Guideline 111
12.3 Bioaccumulative potential

Components:

Gentamicin:
Partition coefficient: n-octanol/water: log Pow: < -2

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107,1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4,68

12.4 Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: log Koc: 4,02

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN number or ID number</td>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN proper shipping name</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>Environmentally hazardous substance, liquid, n.o.s. (clotrimazole, Gentamicin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport hazard class(es)</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M6</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
</tbody>
</table>
Mometasone / Clotrimazole / Gentamicin Formulation

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
14.7 Maritime transport in bulk according to IMO instruments

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation (Annex XIV)

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals


<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Mometasone / Clotrimazole / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

Full text of H-Statements

- **H302**: Harmful if swallowed.
- **H311**: Toxic in contact with skin.
- **H319**: Causes serious eye irritation.
- **H360D**: May damage the unborn child.
- **H360Df**: May damage the unborn child. Suspected of damaging fertility.
- **H361fd**: Suspected of damaging fertility. Suspected of damaging the unborn child.
- **H372**: Causes damage to organs through prolonged or repeated exposure if swallowed.
- **H373**: May cause damage to organs through prolonged or repeated exposure if inhaled.
- **H373**: May cause damage to organs through prolonged or repeated exposure if swallowed.
- **H400**: Very toxic to aquatic life.
- **H410**: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

- **Acute Tox.**: Acute toxicity
- **Aquatic Acute**: Short-term (acute) aquatic hazard
- **Aquatic Chronic**: Long-term (chronic) aquatic hazard
- **Eye Irrit.**: Eye irritation
- **Repr.**: Reproductive toxicity
- **STOT RE**: Specific target organ toxicity - repeated exposure
- **FOR-2011-12-06-1358**: Norway. Occupational Exposure limits
- **FOR-2011-12-06-1358 / TWA**: Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative Structure-Activity Relationship); STOT RE - Specific target organ toxicity - repeated exposure; TWA - Time Weighted Average; TWA - 8-hour Time Weighted Average; WLD50 - Waiting Lethal Dose.
Further information:

Classification of the mixture:
Repr. 1A H360D Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN